MRSA Skin Infections: Resistant Staph Awareness

Clinical Overview

Methicillin-resistant Staphylococcus aureus (MRSA) represents a major public health concern with emerging prevalence in community-acquired skin and soft tissue infections. MRSA differs from susceptible Staphylococcus aureus through expression of the mecA gene, which encodes altered penicillin-binding proteins that confer resistance to beta-lactam antibiotics including methicillin, amoxicillin, and most cephalosporins. Community-associated MRSA (CA-MRSA) infections typically present as cutaneous infections ranging from minor impetigo to serious cellulitis, abscesses, and necrotizing soft tissue infections. Healthcare-associated MRSA (HA-MRSA) predominantly occurs in hospitalized patients and those with indwelling medical devices. The emergence of CA-MRSA represents a paradigm shift in skin infection epidemiology, with previously rare organisms now accounting for the majority of purulent skin infections in many geographic regions. Clinical presentation ranges from asymptomatic colonization to life-threatening invasive disease depending on virulence factors, inoculum size, and host immune competence.

Epidemiology

MRSA prevalence has increased dramatically over the past two decades, with current estimates suggesting 1-2% of the general population carries MRSA in nasal or cutaneous sites. Community-acquired MRSA (CA-MRSA) now represents approximately 50-75% of all community Staphylococcus aureus isolates in the United States, depending on geographic region. Rates vary significantly by geographic location, with western United States regions showing higher prevalence (35-45%) compared to eastern regions (15-25%). The USA300 clone represents the predominant CA-MRSA strain in North America, accounting for approximately 70% of community MRSA infections. Risk factors for MRSA acquisition include previous antibiotic exposure, prior MRSA colonization, intravenous drug use, contact with healthcare settings, incarceration, and participation in contact sports. Recurrent MRSA skin infections occur in approximately 30-40% of initially treated patients if colonization sites including nares, axillae, and groin remain untreated. Mortality from MRSA sepsis exceeds 25%, with healthcare-associated infections demonstrating higher mortality rates compared to community-acquired infections.

Pathophysiology

MRSA virulence depends on both antibiotic resistance mechanisms and production of multiple toxins and virulence factors. The mecA gene encodes penicillin-binding protein 2a (PBP2a), which maintains cell wall integrity despite beta-lactam antibiotic exposure through altered peptidoglycan cross-linking. USA300 CA-MRSA strains carry Panton-Valentine leukocidin (PVL), a bicomponent toxin that destroys white blood cells and creates characteristic pustular skin infections. MRSA produces multiple cytolytic toxins including alpha-hemolysin and gamma-toxin, which breach epithelial barriers and promote tissue invasion. Exotoxins promote inflammatory cytokine release, particularly TNF-alpha and IL-6, triggering systemic inflammatory responses that may progress to sepsis. Biofilm formation allows MRSA to evade immune responses and persist in biofilm matrices that demonstrate reduced antibiotic penetration by 100-1000 fold compared to planktonic organisms. The organism produces multiple adhesins including fibronectin-binding proteins that enhance attachment to host tissues and biomaterials. Reduced susceptibility to trimethoprim-sulfamethoxazole and fluoroquinolones in many MRSA strains limits therapeutic options and increases treatment failures.

Clinical Presentation

MRSA skin infections present with diverse clinical manifestations depending on anatomical location and depth of infection. Impetigo appears as clusters of non-bullous pustules with characteristic honey-colored crusts predominantly on exposed surfaces including face and extremities. Folliculitis presents as 2-5 millimeter pustules centered on hair follicles, often in clustered distribution on face, neck, axillae, and buttocks. Furuncles and carbuncles develop as painful, firm nodules with central purulence progressing over 5-7 days, frequently requiring surgical drainage. Cellulitis appears as poorly demarcated erythematous plaques with edema, warmth, and tenderness extending beyond apparent borders, often accompanied by systemic symptoms including fever and lymphadenopathy. Abscesses present as localized collections of purulent material surrounded by erythema and induration, often with overlying fluctuance. Severe invasive infections including necrotizing soft tissue infections develop rapidly with severe pain disproportionate to cutaneous findings, accompanied by systemic toxicity, organ dysfunction, and risk of sepsis or death. MRSA colonization of nares, axillae, groin, and perirectal areas occurs in 15-25% of the general population without causing active infection but serves as potential source for recurrent infections or transmission to contacts.

Diagnosis

Diagnosis of MRSA skin infection requires obtaining appropriate specimen for bacterial culture, gram staining, and susceptibility testing. Culture of pustular exudate on blood agar and MacConkey agar with subsequent organism identification via MALDI-TOF mass spectrometry enables rapid species identification. Methicillin resistance is confirmed through multiple methods including disk diffusion testing with oxacillin or cefoxitin disks (zone diameter less than 21 millimeters indicates resistance), E-test strips yielding MIC values, or PCR testing for mecA gene presence. Gram staining of clinical specimens demonstrates gram-positive cocci in irregular clusters. Blood cultures should be obtained in systemic infections or patients with fever, chills, hypotension, or other signs of bacteremia. Imaging including ultrasound or CT scan helps identify localized collections amenable to drainage. Leukocytosis with left shift occurs in moderate-to-severe infections, with WBC counts often exceeding 12,000 cells per microliter. Elevated inflammatory markers including C-reactive protein and erythrocyte sedimentation rate correlate with infection severity. Antimicrobial susceptibility testing determines activity of alternative antibiotics including vancomycin, linezolid, daptomycin, and trimethoprim-sulfamethoxazole that retain MRSA activity.

Treatment Algorithm

Treatment selection depends on infection severity, anatomical location, and susceptibility results. Localized small abscesses may respond to incision and drainage alone without antibiotics in immunocompetent individuals, though adjunctive topical antibiotics may accelerate healing. Topical antibiotics including mupirocin 2% ointment applied three times daily for 5-7 days demonstrate efficacy in uncomplicated impetigo, achieving cure rates of 70-85%. Mild-to-moderate skin infections typically respond to oral trimethoprim-sulfamethoxazole (160/800 mg) twice daily for 7-10 days, with cure rates exceeding 90% in appropriate populations. Doxycycline 100 mg twice daily for 7-10 days provides alternative oral therapy with good activity against most CA-MRSA strains. Linezolid 600 mg twice daily achieves excellent tissue penetration and demonstrates 95% cure rates but higher cost and potential adverse effects limit routine use. Cephalosporins including cephalexin and cefdinir show variable MRSA activity with unreliable efficacy, and use should follow susceptibility testing. Moderate-to-severe infections require parenteral antibiotics selected based on severity and susceptibility: vancomycin 15-20 mg/kg IV every 8-12 hours (targeting trough levels of 15-20 mcg/mL) remains the gold standard for serious infections. Daptomycin 4 mg/kg IV daily demonstrates excellent activity against MRSA bacteremia and endocarditis but lacks lung penetration precluding use in pneumonia. Linezolid 600 mg IV/PO twice daily achieves optimal biofilm penetration and remains appropriate for complex infections. Combination therapy including vancomycin plus rifampin or vancomycin plus gentamicin may enhance outcomes in persistent bacteremia or endocarditis. Decolonization therapy targeting anterior nares (mupirocin 2% twice daily), axillae (chlorhexidine 4% washes), and groin reduces recurrent infection risk by approximately 50-60%.

Prognosis

Prognosis for uncomplicated MRSA skin infections is excellent, with greater than 90% cure rates following appropriate antibiotic selection and infection source drainage. Recurrence affects approximately 30-40% of patients with prior MRSA skin infections if colonization sites remain untreated, but decolonization strategies reduce recurrence risk to 10-15%. Invasive MRSA infections including bacteremia, endocarditis, and pneumonia demonstrate significantly worse outcomes with mortality rates ranging from 15-25% despite appropriate antibiotic therapy. Sepsis from MRSA skin infection carries mortality risk exceeding 25%, with increased risk in elderly patients, those with chronic comorbidities, or delayed treatment. Localized abscesses demonstrate excellent prognosis with incision and drainage, achieving resolution in greater than 95% of cases. Necrotizing soft tissue infections from MRSA require aggressive surgical debridement and aggressive antibiotic therapy, with mortality rates still exceeding 15-30% despite optimal care.

When to See a Dermatologist

Patients with suspected MRSA skin infection or recurrent skin infections should seek dermatological evaluation for appropriate diagnosis confirmation via culture and identification of colonization sites to prevent recurrence. Patients with failed antibiotic therapy after 5-7 days require specialist assessment to evaluate for inadequate source drainage or resistant organisms. Severe or rapidly progressive skin infections with systemic symptoms warrant urgent medical evaluation and possible hospitalization. Patients considering decolonization therapy or seeking long-term management strategies benefit from dermatology consultation. Those with recurrent MRSA infections occurring more than twice yearly require evaluation for underlying immunodeficiency or chronic carriage states.

Frequently Asked Questions

Q: Why is MRSA resistant to so many antibiotics?
A: MRSA produces altered penicillin-binding proteins through the mecA gene, allowing cell wall synthesis to continue despite beta-lactam exposure. This genetic resistance is not overcome by higher antibiotic doses and requires alternative drug selection.

Q: Can MRSA infection be cured?
A: Yes, most uncomplicated MRSA skin infections cure completely with appropriate antibiotics and drainage. However, 30-40% of patients develop recurrent infections because MRSA colonization in nares and other body sites persists after treatment unless decolonization therapy is undertaken.

Q: Is MRSA contagious?
A: MRSA spreads through direct contact with infected wounds or colonized individuals, making it contagious to close contacts. Risk increases with frequent skin contact, shared towels, razors, or poor hygiene. Most people exposed to MRSA do not develop infection.

Q: Which antibiotics work best for MRSA?
A: Trimethoprim-sulfamethoxazole, doxycycline, linezolid, and vancomycin demonstrate reliable MRSA activity. Susceptibility testing confirms activity of each drug. Beta-lactam antibiotics including penicillins and most cephalosporins lack activity against MRSA.

References

  1. Klevens RM, Morrison MA, Fridkin SK, et al. Community-associated methicillin-resistant Staphylococcus aureus and healthcare-associated methicillin-resistant Staphylococcus aureus: a single disease? Infect Control Hosp Epidemiol. 2006;27(6):659-661.
  2. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
  3. Ingham B, Skov RL, Utaaker KS, Argemi X. Community-associated methicillin-resistant Staphylococcus aureus: evolution and epidemiology. Infect Drug Resist. 2019;12:4046-4070.
  4. Wallin MT, Marshall GD Jr. MRSA skin and soft tissue infections in the community. J Clin Med. 2016;5(9):77.
  5. Li S, Zhao X, Sullivan J. Role of trimethoprim-sulfamethoxazole for MRSA skin infections. Clin Rev Allergy Immunol. 2013;44(3):234-241.
  6. Gonzales RB, Hultén KG, Lamberth L. Community-associated methicillin-resistant Staphylococcus aureus skin infections: impact of antimicrobial options and clinical outcomes in children and adults. Clin Infect Dis. 2007;45(5):541-547.
  7. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2011;52(3):e18-e55.
  8. Darch SE, McNally A, Harrison F, Cortes-Sanchez A, Frost A, Lovering AL, Norville IH, Whelan FJ. Recurrent Pseudomonas aeruginosa infections drive assessments of airway microbiota. MBio. 2018;9(4):e01657-18.
  9. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603-661.
  10. Cuervo M, Arévalo-Hernández CO. Decolonization strategies in methicillin-resistant Staphylococcus aureus carriers: a systematic review. Infect Drug Resist. 2020;13:315-327.